Green River, WY —June 20, 2019 – Genesis Alkali announced today that a definitive agreement has been reached with Cytozyme Laboratories, Inc. (“Cytozyme”), a privately held company in Salt Lake City, Utah, establishing certain exclusive rights to market and distribute Cytozyme’s LUMENSATM for use in the poultry market.

LUMENSA is a natural feed additive that leverages three modes of action: improved gut integrity, a modified gut biome and the reduction of pathogens through competitive exclusion. This elements combine to support improved gut health and reduce the effects of stress to increase production.

“We are excited to bring Cytozyme’s innovative technology to the poultry market with LUMENSA,” said Wendy Plocher, Genesis Alkali’s Global Animal Nutrition Industry Manager. “We look forward to working with producers to enable them to increase production and improve returns.”

Cytozyme has applied over four decades of experience, knowledge and innovation in fermentation technology to create a diverse portfolio of animal nutrition products. “The growing trend toward antibiotic-free (ABF) diets has brought demand for a greater degree of innovation and product development, geared toward improving animal health and productivity through more natural and sustainable means”, said John Stockham, Cytozyme’s General Manager of Animal Nutrition. “On behalf of Cytozyme, we are excited to contribute to this effort with the help of Genesis Alkali and their deep industry knowledge and relationships.”